What is the specific name of Senno Therapeutics' lead pipeline using iPS cell-derived hepatoblast cells?

The lead pipeline is named SEN-001, developed using allogeneic iPS cell-derived hepatoblast cells.

How much funding in JPY did Senno Therapeutics raise to support SEN-001 development as of the article?

Senno Therapeutics raised 750 million JPY to advance non-clinical and clinical preparations for SEN-001.

What type of cells does Senno Therapeutics use in its cell therapy product SEN-001?

Senno Therapeutics uses allogeneic iPS cell-derived hepatoblast cells in its therapy SEN-001.

What medical condition is Senno Therapeutics targeting with its SEN-001 cell therapy program?

Senno Therapeutics is targeting fatal liver diseases and liver failure with its SEN-001 therapy.

AI News NQ Analysis

Senno Therapeutics Accelerates Development of Cell Therapy Using iPS Cell-Derived Hepatoblast Cells

NQ Score 100/100

AI Summary (NQ-processed)

Senno Therapeutics, a Tokyo-based bioventure, is developing innovative cell therapies for fatal liver diseases using its proprietary allogeneic iPS cell-derived hepatoblast cells. Having raised 750 million JPY, the company plans to use the funds to advance non-clinical development and clinical trial preparations for its lead pipeline, SEN-001, aiming to address critical unmet medical needs in liver failure.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the specific name of Senno Therapeutics' lead pipeline using iPS cell-derived hepatoblast cells?: A: The lead pipeline is named SEN-001, developed using allogeneic iPS cell-derived hepatoblast cells.
Q: How much funding in JPY did Senno Therapeutics raise to support SEN-001 development as of the article?: A: Senno Therapeutics raised 750 million JPY to advance non-clinical and clinical preparations for SEN-001.
Q: Which company is developing allogeneic iPS cell-derived hepatoblast cells for liver disease treatment?: A: Senno Therapeutics, a Tokyo-based bioventure, is developing allogeneic iPS cell-derived hepatoblast cells.
Q: What type of cells does Senno Therapeutics use in its cell therapy product SEN-001?: A: Senno Therapeutics uses allogeneic iPS cell-derived hepatoblast cells in its therapy SEN-001.
Q: What medical condition is Senno Therapeutics targeting with its SEN-001 cell therapy program?: A: Senno Therapeutics is targeting fatal liver diseases and liver failure with its SEN-001 therapy.